Circulating CD4+ and CD8+ T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation

Immunology

Volumn 140, Issue 1, 2013, Pages 87-97

  Funderburg, Nicholas T ^a   Stubblefield Park, Samantha R ^a   Sung, Hannah C ^a   Hardy, Gareth ^a   Clagett, Brian ^a   Ignatz Hoover, James ^a   Harding, Clifford V ^a   Fu, Pingfu ^a   Katz, Jeffry A ^a   Lederman, Michael M ^a   Levine, Alan D ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inflammatory bowel disease; Microbial translocation; T cell activation

Indexed keywords

C REACTIVE PROTEIN; CD38 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 6; KI 67 ANTIGEN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIMULUS LYSATE TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS;

INFLAMMATORY BOWEL DISEASE; MICROBIAL TRANSLOCATION; T-CELL ACTIVATION;

ADULT; ANTIGENS, CD38; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HLA-DR ANTIGENS; HUMANS; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED;

EID: 84883260437     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12114     Document Type: Article

References (43)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis 2011; 17:471-8.
2. Rosenstiel P, Sina C, Franke A, Schreiber S. Towards a molecular risk map - recent advances on the etiology of inflammatory bowel disease. Semin Immunol 2009; 21:334-45.
3. Henderson P, van Limbergen JE, Schwarze J, Wilson DC. Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17:382-95.
4. Soderholm JD, Olaison G, Peterson KH, Franzen LE, Lindmark T, Wiren M, Tagesson C, Sjodahl R. Augmented increase in tight junction permeability by luminal stimuli in the non-inflamed ileum of Crohn's disease. Gut 2002; 50:307-13.
5. Peeters M, Geypens B, Claus D et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997; 113:802-7.
6. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012; 18:968-84.
7. Talley NJ, Abreu MT, Achkar JP et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011; 106(Suppl 1):S2-25.
8. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66:5224-31.
9. Pastor Rojo O, Lopez San Roman A, Albeniz Arbizu E, de la Hera Martinez A, Ripoll Sevillano E, Albillos Martinez A. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:269-77.
10. Pasternak BA, D'Mello S, Jurickova II et al. Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis 2010; 16:856-69.
11. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-71.
12. Sandler NG, Koh C, Roque A et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-30.
13. Papp M, Norman GL, Vitalis Z et al. Presence of anti-microbial antibodies in liver cirrhosis - a tell-tale sign of compromised immunity? PLoS ONE 2010; 5:e12957.
14. Santos-Oliveira JR, Regis EG, Leal CR, Cunha RV, Bozza PT, Da-Cruz AM. Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis. PLoS Negl Trop Dis 2011; 5:e1198.
15. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS ONE 2008; 3:e1915.
16. Baumann H, Gauldie J. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation. Mol Biol Med 1990; 7:147-59.
17. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007; 13:543-51.
18. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005; 11:225-9.
19. Wittig B, Seiter S, Schmidt DS, Zuber M, Neurath M, Zoller M. CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. Lab Invest 1999; 79:747-59.
20. Duivis HE, de Jonge P, Penninx BW, Na BY, Cohen BE, Whooley MA. Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry 2011; 168:913-20.
21. Urbschat A, Obermuller N, Haferkamp A. Biomarkers of kidney injury. Biomarkers 2011; 16(Suppl 1):S22-30.
22. French MA, Oliver BG, Elliott JH, Price P. Plasma biomarkers in the prediction and diagnosis of tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2011; 25:1676-7.
23. Meijer C, Huysen V, Smeenk RT, Swaak AJ. Profiles of cytokines (TNFα and IL-6) and acute phase proteins (CRP and α1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993; 2:359-65.
24. Di Muzio G, Perricone C, Ballanti E et al. Complement system and rheumatoid arthritis: relationships with autoantibodies, serological, clinical features, and anti-TNF treatment. Int J Immunopathol Pharmacol 2011; 24:357-66.
25. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11:707-12.
26. Joseph SB, Miner KT, Croft M. Augmentation of naive, Th1 and Th2 effector CD4 responses by IL-6, IL-1 and TNF. Eur J Immunol 1998; 28:277-89.
27. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009; 15:199-207.
28. + T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011; 121:4170-9.
29. + T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 2010; 16:586-91.
30. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51:289-98.
31. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3:521-33.
32. Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A. Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis. Inflamm Bowel Dis 2005; 11:16-23.
33. Seiderer J, Elben I, Diegelmann J et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008; 14:437-45.
34. Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 2010; 16:1808-13.
35. high T cells in inflammatory bowel disease. Gastroenterology 2005; 128:1868-78.
36. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17:362-81.
37. Kawashima R, Kawamura YI, Oshio T et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice - a pathway associated with ulcerative colitis. Gastroenterology 2011; 141:2119-29.
38. Hopf U, Ramadori G, Moller B, Galanos C. Hepatocellular clearance function of bacterial lipopolysaccharides and free lipid A in mice with endotoxic shock. Am J Emerg Med 1984; 2:13-9.
39. Mowat AM, Bain CC. Mucosal macrophages in intestinal homeostasis and inflammation. J Innate Immun 2011; 3:550-64.
40. Balagopal A, Ray SC, De Oca RM et al. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS 2009; 23:2397-404.
41. Hofer U, Schlaepfer E, Baenziger S et al. Inadequate clearance of translocated bacterial products in HIV-infected humanized mice. PLoS Pathog 2010; 6:e1000867.
42. + T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-59.
43. Gitter AH, Wullstein F, Fromm M, Schulzke JD. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001; 121:1320-8.